Acute and chronic effects of cannabinoids on human cognition - A systematic review

Biological Psychiatry

Volumn 79, Issue 7, 2016, Pages 557-567

  Broyd, Samantha J ^a   Van Hell, Hendrika H ^a   Beale, Camilla ^a   Yücel, Murat ^b   Solowij, Nadia ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Attention; Brain; Cannabis; Cognition; Executive function; Memory

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABIS;

ABSTINENCE; ASSOCIATION; ATTENTION; ATTENTIONAL BIAS; CANNABIS USE; COGNITION; CONVALESCENCE; DECISION MAKING; DELAY DISCOUNTING; EMPIRICAL RESEARCH; EXECUTIVE FUNCTION; HUMAN; LEARNING; LONG TERM EXPOSURE; MEMORY; ONSET AGE; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOMOTOR ACTIVITY; REVIEW; SYSTEMATIC REVIEW; TASK PERFORMANCE; TIME PERCEPTION; VERBAL MEMORY; WORKING MEMORY; CANNABIS ADDICTION; CANNABIS SMOKING; CHEMICALLY INDUCED; COGNITIVE DEFECT; DRUG EFFECTS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE;

ATTENTION; CANNABINOIDS; CANNABIS; COGNITION; COGNITION DISORDERS; EXECUTIVE FUNCTION; HUMANS; MARIJUANA ABUSE; MARIJUANA SMOKING; MEMORY; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; VERBAL LEARNING;

EID: 84961772511     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.12.002     Document Type: Review

References (150)

1. AIHW (2013): National Drug Strategy Household Survey. Canberra: Australian Institute of Health and Welfare.
2. UNDOC (2014): World Drug Report 2014. Vienna: United Nations Office on Drugs and Crime.
3. Volkow ND, Compton WM, Weiss SR (2014): Adverse health effects of marijuana use. N Engl J Med 371:879.
4. Hall W, Degenhardt L (2014): The adverse health effects of chronic cannabis use. Drug Test Anal 6:39-45.
5. Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogue S, et al. (2013): Structural and functional imaging studies in chronic cannabis users: A systematic review of adolescent and adult findings. PLoS One 8:e55821.
6. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yücel M (2010): Structural MRI findings in long-term cannabis users: What do we know? Subst Use Misuse 45:1787-1808.
7. Lorenzetti V, Solowij N, Fornito A, Lubman DI, Yucel M (2014): The association between regular cannabis exposure and alterations of human brain morphology: An updated review of the literature. Curr Pharm Des 20:2138-2167.
8. James A, James C, Thwaites T (2013): The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: A systematic review. Psychiatry Res 214:181-189.
9. Bossong MG, Jager G, Bhattacharyya S, Allen P (2014): Acute and non-acute effects of cannabis on human memory function: A critical review of neuroimaging studies. Curr Pharm Des 20: 2114-2125.
10. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P (2009): Imaging the neural effects of cannabinoids: Current status and future opportunities for psychopharmacology. Curr Pharm Des 15:2603-2614.
11. Martin-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, Allen P, et al. (2010): Neuroimaging in cannabis use: A systematic review of the literature. Psychol Med 40:383-398.
12. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. (2007): Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370: 319-328.
13. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. (2015): Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A casecontrol study. Lancet Psychiatry 2:233-238.
14. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP (2015): Cannabis use and mania symptoms: A systematic review and meta-analysis. J Affect Disord 171:39-47.
15. Radhakrishnan R, Wilkinson ST, D'Souza DC (2014): Gone to pot-a review of the association between cannabis and psychosis. Front Psychiatry 5:54.
16. Chadwick B, Miller ML, Hurd YL (2013): Cannabis use during adolescent development: Susceptibility to psychiatric illness. Front Psychiatry 4:129.
17. Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, et al. (2014): Young adult sequelae of adolescent cannabis use: An integrative analysis. Lancet Psychiatry1: 286-293.
18. Solowij N, Battisti R (2008): The chronic effects of cannabis on memory in humans: A review. Curr Drug Abuse Rev 1:81-98.
19. Solowij N, Michie PT (2007): Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32:30-52.
20. Solowij N, Pesa N (2010): Cognitive abnormalities and cannabis use. Rev Bras Psiquiatria 32:S31-S40.
21. Solowij N, Pesa N (2012): Cannabis and cognition: Short and longterm effects. In: Castle D, Murray R, D'Souza DC, editors. Marijuana and Madness, 2nd ed. Cambridge: Cambridge University Press, 91-102.
22. Crean RD, Crane NA, Mason BJ (2011): An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5:1-8.
23. Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng W-S, et al. (2007): [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104: 9800-9805.
24. Lubman DI, Cheetham A, Yücel M (2015): Cannabis and adolescent brain development. Pharmacol Ther 148c:1-16.
25. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002): Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 325:1212-1213.
26. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003): Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15-21.
27. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002): Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 156:319-327.
28. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002): Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ 325:1199.
29. Leweke FM, Gerth CW, Klosterkotter J (2004): Cannabis-associated psychosis: Current status of research. CNS Drugs 18:895-910.
30. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. (2010): Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764-774.
31. Batalla A, Crippa JA, Busatto GF, Guimaraes FS, Zuardi AW, Valverde O, et al. (2014): Neuroimaging studies of acute effects of THC and CBD in humans and animals: A systematic review. Curr Pharm Des 20:2168-2185.
32. Lorenzetti V, Solowij N, Yücel M (2016): The role of cannabinoids on neuroanatomical alterations in cannabis users. Biol Psychiatry 79: e17-e31.
33. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009): Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. PLoS Med 6:e1000097.
34. Fletcher PC, Honey GD (2006): Schizophrenia, ketamine and cannabis: Evidence of overlapping memory deficits. Trends Cogn Sci 10:167-174.
35. Ranganathan M, D'Souza D (2006): The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology 188: 425-444.
36. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. (2004): The psychotomimetic effects of intravenous delta- 9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29:1558-1572.
37. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, et al. (2008): Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology 198:587-603.
38. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, et al. (2009): The acute effects of synthetic intravenous delta-9- tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39:1607-1616.
39. Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, et al. (2012): Naltrexone does not attenuate the effects of intravenous delta-9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol 15:1251-1264.
40. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. (2013): Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19-27.
41. Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al. (2010): Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 24: 1697-1708.
42. Theunissen EL, Heckman P, de Sousa Fernandes Perna EB, Kuypers KP, Sambeth A, Blokland A, et al. (2015): Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology 232:343-353.
43. Wesnes KA, Annas P, Edgar CJ, Deeprose C, Karlsten R, Philipp A, et al. (2010): Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol 24:1659-1669.
44. Morgan CJ, Schafer G, Freeman TP, Curran HV (2010): Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study: Naturalistic study [corrected]. Br J Psychiatry 197:285-290.
45. Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A, et al. (2013): Impulsivity, attention, memory, and decisionmaking among adolescent marijuana users. Psychopharmacology 226:307-319.
46. Harvey MA, Sellman JD, Porter RJ, Frampton CM (2007): The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev 26:309-319.
47. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, et al. (2011): Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology 216: 131-144.
48. Becker MP, Collins PF, Luciana M (2014): Neurocognition in collegeaged daily marijuana users. J Clin Exp Neuropsychol 36:379-398.
49. Cuttler C, McLaughlin RJ, Graf P (2012): Mechanisms underlying the link between cannabis use and prospective memory. PLoS One 7: e36820.
50. Gonzalez R, Schuster RM, Mermelstein RJ, Vassileva J, Martin EM, Diviak KR (2012): Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders. J Clin Exp Neuropsychol 34:962-976.
51. Looby A, Earleywine M (2010): Gender moderates the impact of stereotype threat on cognitive function in cannabis users. Addict Behav 35:834-839.
52. Macher RB, Earleywine M (2012): Enhancing neuropsychological performance in chronic cannabis users: The role of motivation. J Clin Exp Neuropsychol 34:405-415.
53. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE (2012): Age of onset of marijuana use and executive function. Psychol Addict Behav 26:496-506.
54. Lisdahl KM, Price JS (2012): Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol Soc 18:678-688.
55. Hanson KL, Winward JL, Schweinsburg AD, Medina KL, Brown SA, Tapert SF (2010): Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Addict Behav 35: 970-976.
56. Crane NA, Schuster RM, Gonzalez R (2013): Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc 19:1009-1015.
57. Thames AD, Arbid N, Sayegh P (2014): Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav 39:994-999.
58. Wagner D, Becker B, Gouzoulis-Mayfrank E, Daumann J (2010): Interactions between specific parameters of cannabis use and verbal memory. Prog Neuropsychopharmacol Biol Psychiatry 34:871-876.
59. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. (2002): Cognitive functioning of long term heavy cannabis users seeking treatment. JAMA 287:1123-1131.
60. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. (2012): Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109: E2657-E2664.
61. Messinis L, Kyprianidou A, Malefaki S, Papathanasopoulos P (2006): Neuropsychological deficits in long-term frequent cannabis users. Neurology 66:737-739.
62. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. (2012): Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42:391-400.
63. Roten A, Baker NL, Gray KM (2015): Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav 45:119-123.
64. Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, et al. (2004): Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med 34:1239-1250.
65. Medina KL, Hanson KL, Schweinsburf AD, Cohen-Zion M, Nafel BJ, Tapert SF (2007): Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc 13:807-820.
66. Tait RJ, Mackinnon A, Christensen H (2011): Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 106:2195-2203.
67. Winward JL, Hanson KL, Tapert SF, Brown SA (2014): Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements. J Int Neuropsychol Soc 20:784-795.
68. Bedi G, Cooper ZD, Haney M (2013): Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol 18:872-881.
69. Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, et al. (2015): How cannabis causes paranoia: Using the intravenous administration of Δ9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull 41: 391-399.
70. Hunault CC, Mensinga TT, Bocker KB, Schipper CM, Kruidenier M, Leenders ME, et al. (2009): Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology 204:85-94.
71. Kollins SH, Schoenfelder EN, English JS, Holdaway A, Van Voorhees E, O'Brien BR, et al. (2015): An exploratory study of the combined effects of orally administered methylphenidate and delta-9- tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. J Subst Abuse Treat 48: 96-103.
72. Lane SD, Cherek DR, Lieving LM, Tcheremissine OV (2005): Marijuana effects on human forgetting functions. J Exp Anal Behav 83:67-83.
73. Lile JA, Kelly TH, Hays LR (2011): Separate and combined effects of the cannabinoid agonists nabilone and delta(9)-THC in humans discriminating delta(9)-THC. Drug Alcohol Depend 116:86-92.
74. Lile JA, Kelly TH, Hays LR (2014): Separate and combined effects of the GABA-A positive allosteric modulator diazepam and delta(9)- THC in humans discriminating delta(9)-THC. Drug Alcohol Depend 143:141-148.
75. Makela P, Wakeley J, Gijsman H, Robson PJ, Bhagwagar Z, Rogers RD (2006): Low doses of Δ-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. Neuropsychopharmacology 31:462-470.
76. Ramesh D, Haney M, Cooper ZD (2013): Marijuana's dosedependent effects in daily marijuana smokers. Exp Clin Psychopharmacol 21:287-293.
77. Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D (2013): The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 128:64-70.
78. Whitlow CT, Liguori A, Brooke Livengood L, Hart SL, Mussat- Whitlow BJ, Lamborn CM, et al. (2004): Long-term heavy marijuana users make costly decisions on a gambling task. Drug Alcohol Depend 76:107-111.
79. Fried PA, Watkinson B, Gray R (2005): Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicol Teratol 27:231-239.
80. Wadsworth EJ, Moss SC, Simpson SA, Smith AP (2006): Cannabis use, cognitive performance and mood in a sample of workers. J Psychopharmacol 20:14-23.
81. Herzig DA, Nutt D, Mohr C (2014): Alcohol and relatively pure cannabis use, but not schizotypy, are associated with cognitive attenuations. Front Psychiatry 5:133.
82. Grant JE, Chamberlain SR, Schreiber L, Odlaug BL (2012): Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend 121:159-162.
83. Scholes KE, Martin-Iverson MT (2010): Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychol Med 40:1635-1646.
84. Verdejo-García A, Beatriz Fagundo A, Cuenca A, Rodriguez J, Cuyás E, Langohr K, et al. (2013): COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology 38:1598-1606.
85. Hanson KL, Thayer RE, Tapert SF (2014): Adolescent marijuana users have elevated risk-taking on the balloon analog risk task. J Psychopharmacol 28:1080-1087.
86. Anderson BM, Rizzo M, Block RI, Pearlson GD, O'Leary DS (2010): Sex, drugs, and cognition: Effects of marijuana. J Psychoactive Drugs 42:413-424.
87. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. (2008): Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33:2505-2516.
88. Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, et al. (2012): Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: A randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. J Clin Psychopharmacol 32: 492-502.
89. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009): Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23: 266-277.
90. Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA (2012): Psychomotor performance, subjective and physiological effects and whole blood Delta(9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol 36:405-412.
91. Bosker WM, Karschner EL, Lee D, Goodwin RS, Hirvonen J, Innis RB, et al. (2013): Psychomotor function in chronic daily Cannabis smokers during sustained abstinence. PLoS One 8:e53127.
92. Huijbregts SC, Griffith-Lendering MF, Vollebergh WA, Swaab H (2014): Neurocognitive moderation of associations between cannabis use and psychoneuroticism. J Clin Exp Neuropsychol 36: 794-805.
93. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. (2012): A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37:1689-1698.
94. Shannon EE, Mathias CW, Dougherty DM, Liguori A (2010): Cognitive impairments in adolescent cannabis users are related to THC levels. Addict Dis Treat 9:158-163.
95. Hooper SR, Woolley D, De Bellis MD (2014): Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. Psychopharmacology 231:1467-1477.
96. Beraha EM, Cousijn J, Hermanides E, Goudriaan AE, Wiers RW (2013): Implicit associations and explicit expectancies toward cannabis in heavy cannabis users and controls. Front Psychiatry 4:59.
97. Cane JE, Sharma D, Albery IP (2009): The addiction Stroop task: Examining the fast and slow effects of smoking and marijuanarelated cues. J Psychopharmacol 23:510-519.
98. Cousijn J, Watson P, Koenders L, Vingerhoets WA, Goudriaan AE, Wiers RW (2013): Cannabis dependence, cognitive control and attentional bias for cannabis words. Addict Behav 38:2825-2832.
99. Field M (2005): Cannabis "dependence" and attentional bias for cannabis-related words. Behav Pharmacol 16:473-476.
100. Field M, Eastwood B, Bradley BP, Mogg K (2006): Selective processing of cannabis cues in regular cannabis users. Drug Alcohol Depend 85:75-82.
101. Field M, Mogg K, Bradley BP (2004): Cognitive bias and drug craving in recreational cannabis users. Drug Alcohol Depend 74:105-111.
102. Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010): Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35:1879-1885.
103. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006): High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31:2296-2303.
104. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G (2006): Cognition and motor control as a function of delta-9-THC concentration in serum and oral fluid: Limits of impairment. Drug Alcohol Depend 85:114-122.
105. Lane SD, Cherek DR, Pietras CJ, Tcheremissine OV (2004): Acute marijuana effects on response-reinforcer relations under multiple variable-interval schedules. Behav Pharmacol 15:305-309.
106. Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. (2008): A study investigating the acute dose-response effects of 13mg and 17mg delta 9-tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol 22:441-451.
107. Kaufmann RM, Kraft B, Frey R, Winkler D, Weiszenbichler S, Bδcker C, et al. (2010): Acute psychotropic effects of oral cannabis extract with a defined content of δ9-Tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry 43:24-32.
108. Flavel SC, White JM, Todd G (2013): Abnormal maximal finger tapping in abstinent cannabis users. Hum Psychopharmacol 28: 612-614.
109. Metrik J, Kahler CW, Reynolds B, McGeary JE, Monti PM, Haney M, et al. (2012): Balanced placebo design with marijuana: Pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology 223:489-499.
110. Fisk JE, Montgomery C (2008): Real-world memory and executive processes in cannabis users and non-users. J Psychopharmacol 22: 727-736.
111. Palermo L, Bianchini F, Iaria G, Tanzilli A, Guariglia C (2012): Assessing topographical orientation skills in cannabis users. Sci World J 2012:137071.
112. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al. (2011): Frontal Assessment Battery (FAB) is a simple tool for detecting executive deficits in chronic cannabis users. J Clin Exp Neuropsychol 33:523-531.
113. Lane SD, Cherek DR, Tcheremissine OV, Steinberg JL, Sharon JL (2007): Response perseveration and adaptation in heavy marijuanasmoking adolescents. Addict Behav 32:977-990.
114. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al. (2011): Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 198:442-447.
115. Day AM, Metrik J, Spillane NS, Kahler CW (2013): Working memory and impulsivity predict marijuana-related problems among frequent users. Drug Alcohol Depend 131:171-174.
116. Griffith-Lendering MF, Huijbregts SC, Vollebergh WA, Swaab H (2012): Motivational and cognitive inhibitory control in recreational cannabis users. J Clin Exp Neuropsychol 34:688-697.
117. Moreno M, Estevez AF, Zaldivar F, Montes JM, Gutierrez-Ferre VE, Esteban L, et al. (2012): Impulsivity differences in recreational cannabis users and binge drinkers in a university population. Drug Alcohol Depend 124:355-362.
118. Vivas AB, Estevez AF, Moreno M, Panagis G, Flores P (2012): Use of cannabis enhances attentional inhibition. Hum Psychopharmacol 27: 464-469.
119. McHale S, Hunt N (2008): Executive function deficits in short-term abstinent cannabis users. Hum Psychopharmacol 23:409-415.
120. Rogers RD, Wakeley J, Robson PJ, Bhagwagar Z, Makela P (2007): The effects of low doses of delta-9 tetrahydrocannabinol on reinforcement processing in the risky decision-making of young healthy adults. Neuropsychopharmacology 32:417-428.
121. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ (2005): Acute marijuana effects on human risk taking. Neuropsychopharmacology 30:800-809.
122. Vadhan NP, Hart CL, van Gorp WG, Gunderson EW, Haney M, Foltin RW (2007): Acute effects of smoked marijuana on decision making, as assessed by a modified gambling task, in experienced marijuana users. J Clin Exp Neuropsychol 29:357-364.
123. Fridberg DJ, Queller S, Ahn WY, Kim W, Bishara AJ, Busemeyer JR, et al. (2010): Cognitive mechanisms underlying risky decision-making in chronic cannabis users. J Math Psychol 54:28-38.
124. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, et al. (2012): Reflection impulsivity in adolescent cannabis users: A comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology 219:575-586.
125. Gilman JM, Calderon V, Curran MT, Evins AE (2015): Young adult cannabis users report greater propensity for risk-taking only in nonmonetary domains. Drug Alcohol Depend 147:26-31.
126. Hermann D, Lemenager T, Gelbke J, Welzel H, Skopp G, Mann K (2009): Decision making of heavy cannabis users on the Iowa Gambling Task: Stronger association with THC of hair analysis than with personality traits of the Tridimensional Personality Questionnaire. Eur Addict Res 15:94-98.
127. Verdejo-Garcia A, Benbrook A, Funderburk F, David P, Cadet JL, Bolla KI (2007): The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend 90:2-11.
128. Johnson MW, Bickel WK, Baker F, Moore BA, Badger GJ, Budney AJ (2010): Delay discounting in current and former marijuana-dependent individuals. Exp Clin Psychopharmacol 18:99-107.
129. SAMHSA (2013): Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, DHHS Publication No. SMA 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration.
130. Fattore L, Fratta W (2010): How important are sex differences in cannabinoid action? Br J Pharmacol 160:544-548.
131. McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF (2011): Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 224:128-134.
132. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF (2009): Prefrontal cortex morphometry in abstinent adolescent marijuana users: Subtle gender effects. Addict Biol 14:457-468.
133. Hartman RL, Huestis MA (2013): Cannabis effects on driving skills. Clin Chem 59:478-492.
134. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001): Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909-915.
135. Schreiner AM, Dunn ME (2012): Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A metaanalysis. Exp Clin Psychopharmacol 20:420-429.
136. Mechoulam R, Parker LA (2013): The endocannabinoid system and the brain. Annu Rev Psychol 64:21-47.
137. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012): Endocannabinoid signaling and synaptic function. Neuron 76:487-492.
138. Fratta W, Fattore L (2013): Molecular mechanisms of cannabinoid addiction. Curr Opin Neurobiol 23:70-81.
139. Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, et al. (2012): Effect of long-term cannabis use on axonal fibre connectivity. Brain 135:2245-2255.
140. Yücel M, Lorenzetti V, Suo C, Zalesky A, Fornito A, Takagi M, et al. (2016): Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry 6:e710. http://dx.doi.org/10.1038/tp.2015.201.
141. Solowij N (1995): Do cognitive impairments recover following cessation of cannabis use? Life Sci 56:2119-2126.
142. McClure EA, Lydiard JB, Goddard SD, Gray KM (2015): Objective and subjective memory ratings in cannabis-dependent adolescents. Am J Addict 24:47-52.
143. Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, et al. (2011): A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 26:224-236.
144. Morgan CJ, Rothwell E, Atkinson H, Mason O, Curran HV (2010): Hyper-priming in cannabis users: A naturalistic study of the effects of cannabis on semantic memory function. Psychiatry Res 176:213-218.
145. Bartholomew J, Holroyd S, Heffernan TM (2010): Does cannabis use affect prospective memory in young adults? J Psychopharmacol 24: 241-246.
146. Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM (2009): Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci 259:284-292.
147. Keen L, Turner AD (2014): Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults. J Int Neuropsychol Soc 20:773-783.
148. Lieving LM, Lane SD, Cherek DR, Tcheremissine OV (2006): Effects of marijuana on temporal discriminations in humans. Behav Pharmacol 17:173-183.
149. Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, et al. (2013): Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology 226: 401-413.
150. Martin-Soelch C, Kobel M, Stoecklin M, Michael T, Weber S, Krebs B, et al. (2009): Reduced response to reward in smokers and cannabis users. Neuropsychobiology 60:94-103.